This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis
Phase 1
- Conditions
- Dermatitis atopicMedDRA version: 20.0Level: PTClassification code: 10012438Term: Dermatitis atopic Class: 100000004858Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- CTIS2023-504869-23-00
- Lead Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 438
Inclusion Criteria
Male or female subjects =18 and < 65 years of age at the Screening Visit, Chronic AD with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria, Candidate for systemic treatment
Exclusion Criteria
Prior exposure to any JAK inhibitor, Unable or unwilling to discontinue current AD treatments prior to the study, Requirement of prohibited medications during the study treatment, Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method